Literature DB >> 16265708

Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.

Gabriele Simonini1, Laura Masi, Teresa Giani, Elisabetta Piscitelli, Rolando Cimaz, Silvia Vierucci, Maria Luisa Brandi, Fernanda Falcini.   

Abstract

OBJECTIVE: Emerging evidence from in vitro studies and mouse genetics attributes to osteoprotegerin (OPG), a member of the tumor necrosis factor receptor family, an important role in vascular biology. We evaluated serum levels of OPG in a group of children with Kawasaki disease (KD), before immunoglobulin (IVIG) infusion and at 3-month followup.
METHODS: Fifty patients (38 boys, 20 girls, median age 3.6 yrs, range 4 mo-7.4 yrs) fulfilling criteria for the diagnosis of KD, 30 febrile controls with infectious diseases, 18 patients with juvenile systemic lupus erythematosus (JSLE), and 40 healthy controls were enrolled. All KD patients received IVIG treatment within the first 10 days of illness, and aspirin. Coronary artery abnormalities (CAA) were reported in 6 out of 58 patients; all were male and younger than 5 years. Serum OPG was measured by ELISA in patients with KD before IVIG and at 3-month followup (median time 3.2 mo, range 3-3.5).
RESULTS: At baseline and at the 3-month followup, KD patients had significantly higher OPG serum levels than febrile controls (p < 0.001 and p < 0.004, respectively), JSLE patients (p < 0.0001), and healthy controls (p < 0.0001). At baseline, KD patients who developed CAA had higher OPG serum levels than those without CAA (p = 0.0001); this difference was not present at 3-month followup. The optimal OPG cutoff value of 123.2 pg/ml was a significant predictor for CAA, with a sensitivity of 100% (6/6), a specificity of 96% (50/52), and a positive predictive value of 75% (6/8).
CONCLUSION: High OPG levels might be the result of compensatory production during acute and subacute phases of KD. OPG assay might be an additional clinically useful marker to monitor and differentiate patients who develop, from those who do not develop, such coronary artery abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265708

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

2.  Late-appearing brachiocephalic aneurysm: an atypical vascular sequella of Kawasaki disease.

Authors:  Gaby Yang; Deborah Thompson; Andrew Warren
Journal:  Pediatr Cardiol       Date:  2008-08-15       Impact factor: 1.655

3.  Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels.

Authors:  Johnny S H Kwan; Yi-Hsiang Hsu; Ching-Lung Cheung; Josée Dupuis; Aude Saint-Pierre; Joel Eriksson; Samuel K Handelman; Aaron Aragaki; David Karasik; Peter P Pramstaller; Charles Kooperberg; Andrea Z Lacroix; Martin G Larson; Kam-Shing Lau; Mattias Lorentzon; Irene Pichler; Pak C Sham; Daniel Taliun; Liesbeth Vandenput; Douglas P Kiel; Andrew A Hicks; Rebecca D Jackson; Claes Ohlsson; Emelia J Benjamin; Annie W C Kung
Journal:  Hum Mol Genet       Date:  2014-07-30       Impact factor: 6.150

4.  Pediatric Kawasaki Disease and Adult Human Immunodeficiency Virus Kawasaki-Like Syndrome Are Likely the Same Malady.

Authors:  Raymond M Johnson; Kelly R Bergmann; John J Manaloor; Xiaoqing Yu; James E Slaven; Anupam B Kharbanda
Journal:  Open Forum Infect Dis       Date:  2016-09-29       Impact factor: 3.835

5.  Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease.

Authors:  Alex Kentsis; Andrew Shulman; Saima Ahmed; Eileen Brennan; Michael C Monuteaux; Young-Ho Lee; Susan Lipsett; Joao A Paulo; Fatma Dedeoglu; Robert Fuhlbrigge; Richard Bachur; Gary Bradwin; Moshe Arditi; Robert P Sundel; Jane W Newburger; Hanno Steen; Susan Kim
Journal:  EMBO Mol Med       Date:  2012-12-20       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.